Key Takeaways
- Transition quarter, multi-vertical now real: Standalone revenue grew +20.2% YoY as logistics normalized and SPL Infusion recorded its first-ever revenue, marking the shift from a single-engine injectable business to a multi-vertical platform.
- Oral segment surged, injectables dipped: Oral revenues jumped 153.3% YoY to INR8.6 crores while injectables declined 9.7%, a product-mix swing that also lifted EBITDA margin to 18.4%.
- SPL Infusion is the FY27 story: The Pune facility contributed INR1.2 crores in its debut quarter, with management targeting INR60–65 crores in FY27 and peak revenue above INR120–130 crores.
- Margins improved on mix, not yet on scale: EBITDA margin expanded 220 bps YoY to 18.4%, driven by the product mix shipped; base business margins are expected to hold at 16–17% while the infusion business targets 17–18% initially.
- What to watch next quarter: The Q4 ramp at SPL Infusion (management hinted at double-digit crores), the PPP project update, and whether the base business growth acceleration toward 25% materializes from Q2 FY27 as guided.
SPL Infusion: The New Growth Engine
- First revenue recorded: The Pune infusion facility contributed INR1.2 crores in consolidated revenue for Q3 FY26, its first quarter of operations, and management expects Q4 to be significantly higher, potentially reaching double-digit crores.
- FY27 revenue target: Management is targeting INR60–65 crores from SPL Infusion in FY27, with utilization ramping from the current 20–25% to 40–50% over the year.
- Peak potential: At full capacity, SPL Infusion is expected to exceed INR120–130 crores in revenue with an EBITDA margin of 19–20%.
- Product portfolio build-out: The company is deliberately pacing its ramp to assemble a portfolio of 20–23 products by November/December, well above the 12–14 products competitors typically carry, with specialized products currently in stability studies.
- Utilization ramp is approval-gated: The projected 40–50% utilization for FY27 reflects that new product approvals arrive month-by-month and specialized products take time to develop, so the ramp is back-end loaded.
Ashwani Khemka: "That is the reason we are going slow on this thing so that by the end of November, December, we have a good product portfolio of around 20 to 23 products, which most of the competitors do not have."
Base Business: Injectables, Orals & the Mix Shift
- Injectable revenues declined: The legacy injectable business fell 9.7% YoY to INR11.7 crores, a decline management attributed to product mix rather than demand weakness, with logistics normalization helping shipment volumes recover from the prior quarter.
- Oral segment exploded: Oral revenues surged 153.3% YoY to INR8.6 crores, fundamentally reshaping the revenue composition and contributing to the margin uplift.
- Nutraceutical contribution: The nutraceutical segment added INR0.56 crores in the quarter, with the Prague venture gaining momentum and building a pipeline of potential business from European markets.
- FY26 base business closing: Management expects the core Sanjivani business to close FY26 at INR72–75 crores, with FY27 targeting approximately INR90 crores.
- Growth acceleration expected from H1 FY27: Base business growth is expected to accelerate from Q2 or Q3 of FY27, potentially reaching 25%, with long-term growth pegged at 18–20% and further upside if West/East Africa approvals come through in FY27–FY28.
Margins: Mix-Led Expansion, Utilization-Led Ambition
- EBITDA margin expanded on product mix: Standalone EBITDA margin rose to 18.4% from 16.2% YoY, driven entirely by the product mix shipped during the quarter; management cautioned that quarterly fluctuations are normal but the trajectory is upward.
- Base business margin steady: The base business EBITDA margin is expected to remain in the 16–17% range, consistent with the last nine months.
- Infusion margin targets: SPL Infusion is targeting 17–18% EBITDA margin initially, improving toward 19–20% as utilization scales toward peak capacity.
- Capex is maintenance-level: FY27 capex for the base business plants in Mumbai and Dehradun is pegged at INR4–4.5 crores, directed at maintenance and upgrades rather than expansion.
Regulatory & Compliance Edge
- Schedule M compliance achieved: All company plants are compliant with the revised Schedule M standards enforced by the FDA, a threshold management estimates only 20–30% of Indian plants will meet, positioning Sanjivani ahead of a large swath of the domestic industry.
- PPP project still alive: A previously disclosed PPP project remains in the pipeline, with management deferring a substantive update to the Q4 results call.
Srivardhan Khemka: "I'm happy to report that all our plants are compliant with the revised Schedule M, in which from our estimates in our country, there are only 20% to 30% of the plants who will actually comply."
Capital & Shareholding
- Warrant conversion complete: All warrants issued to promoters have been converted and the corresponding funds received, removing a potential overhang.
- Promoters intend to increase stake: Promoters plan to increase their shareholding year-on-year, subject to the regulatory 5% annual limit.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Base business FY26 revenue | INR72–75 crores | FY26 close |
| Base business FY27 revenue | ~INR90 crores | FY27 |
| SPL Infusion FY27 revenue | INR60–65 crores | FY27 |
| SPL Infusion utilization | 40–50% (from 20–25% currently) | FY27 |
| SPL Infusion product portfolio | 20–23 products | By Nov/Dec (calendar year) |
| SPL Infusion peak revenue | >INR120–130 crores | At peak capacity (undated) |
| SPL Infusion peak EBITDA margin | 19–20% | At peak capacity (undated) |
| Base business growth acceleration | Potentially reaching 25% | From Q2 or Q3 FY27 |
| Base business long-term growth | 18–20% (higher with Africa approvals) | FY27–FY28 and beyond |
| Base business EBITDA margin | 16–17% | Sustaining range |
| SPL Infusion initial EBITDA margin | 17–18% | Initial phase |
| FY27 base business capex | INR4–4.5 crores | FY27 |
| PPP project update | Deferred to Q4 results | Q4 FY26 call |
| Promoter shareholding increase | Year-on-year increase (subject to 5% cap) | Ongoing |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Standalone revenue | ₹20.9 cr, +20.2% YoY |
| Consolidated revenue | ₹22.1 cr, +27.1% YoY |
| Standalone EBITDA | ₹3.9 cr, +36% YoY |
| Consolidated EBITDA | ₹14.1 cr, +44.8% YoY |
| Standalone EBITDA margin | 18.4%, vs 16.2% in Q3 FY25 |
| Consolidated EBITDA margin | 18.5%, vs 16.2% in Q3 FY25 |
| Standalone PAT | ₹2.6 cr, +37.9% YoY |
| Consolidated PAT | ₹2.38 cr, +46.3% YoY |
| Consolidated PAT after non-controlling interest | ₹2.7 cr, +42.6% YoY |
| Injectable segment revenue | ₹11.7 cr, -9.7% YoY |
| Oral segment revenue | ₹8.6 cr, +153.3% YoY |
| Nutraceutical segment revenue | ₹0.56 cr |
| SPL Infusion (Pune) first-time revenue contribution | ₹1.2 cr |
| Export share of total revenue | 76.9%, core markets Middle East, Africa, Latin America |
| SPL Infusion current capacity utilization | 20% to 25% |
| FY27 base business revenue target | ~₹90 cr |
| FY27 SPL Infusion revenue target | ₹60 cr to ₹65 cr |
| SPL Infusion peak revenue potential | above ₹120 cr to ₹130 cr |
| SPL Infusion peak EBITDA margin target | 19% to 20% |
| FY27 base business capex plan | ₹4 cr to ₹4.5 cr |
| Base business EBITDA margin trajectory (9M FY26) | 16% to 17% |
| Pune business early-stage EBITDA target | 17% to 18%, expected to rise with utilization |